• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 11
  3. Author

Online ISSN: 2515-8260

Volume7, Issue11

Scientific Clinical Validation Of Siddha Drug Ayabirungarajakarpam For Iron Defeciency Anemia: Single Arm Non-Randomized Study

    Nagalingam Varnakulendran, Veeriah Elango

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 11, Pages 1392-1403

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

The main focus of this study is to provide scientific validation ofAyabirungarajakarpam(ABK), a herbo-metallic synergistic Siddha formulation which is commonly used as anti-anemic drug. The herbal formulations have been the source of treatment of anemia before the invention of synthetic medicines because the diseases are born with human and drug came in to existence since a very early period to relieve people from their ailments. The traditional medicine which is in use from the time immemorial are found to be derived from natural sources because of remarkable therapeutic effects and less side effects. The 116 Iron deficiency anemic(IDA) patients both sex with age limit range of 19-60 with the typical clinical signs of IDA and the Hb within the range of 7-11gm/dl were enrolled after obtaining written consent.The patients were asked to attend the OPD once in fifteen days to collect the medicines as well as to assess the physical complain. The laboratory investigation was performed three times 0th, 48th, 90th day during the course of study. The trial drug Ayabirungarajakarpam 500mg with lime juice twice a day was given for 48 days and then the patients were asked to attend the OPD 72th  day to assess the clinical signs and 90th day to assess clinical signs as well as the laboratory investigation..The patients treated with ABK has got relief more than 90% for all the signs and symptoms reported here and well as significant increased in Hb, RBC,PCV, haematological indices and improvement of peripheral blood smear indicate the potency of ABK in reducing symptoms and haematinic activity. No any treatment related side effects have been reported during the course of study. Hence, ABK can be claimed as safe drug for oral therapy in human for the management of IDA.
Keywords:
  • PDF (256 K)
  • XML
(2020). Scientific Clinical Validation Of Siddha Drug Ayabirungarajakarpam For Iron Defeciency Anemia: Single Arm Non-Randomized Study. European Journal of Molecular & Clinical Medicine, 7(11), 1392-1403.
Nagalingam Varnakulendran, Veeriah Elango. "Scientific Clinical Validation Of Siddha Drug Ayabirungarajakarpam For Iron Defeciency Anemia: Single Arm Non-Randomized Study". European Journal of Molecular & Clinical Medicine, 7, 11, 2020, 1392-1403.
(2020). 'Scientific Clinical Validation Of Siddha Drug Ayabirungarajakarpam For Iron Defeciency Anemia: Single Arm Non-Randomized Study', European Journal of Molecular & Clinical Medicine, 7(11), pp. 1392-1403.
Scientific Clinical Validation Of Siddha Drug Ayabirungarajakarpam For Iron Defeciency Anemia: Single Arm Non-Randomized Study. European Journal of Molecular & Clinical Medicine, 2020; 7(11): 1392-1403.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 43
  • PDF Download: 85
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  info@ejmcm.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

Editorial Team:  editor@ejmcm.com

For Special Issue Proposal : chiefeditor.ejmcm@gmail.com / info@ejmcm.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus